Glowise editorial guide

Can Tirzepatide Cause Blood Clots? Read the Evidence and Know When to Act

Case reports, trial analyses, and safety-report databases answer different questions about tirzepatide and blood clots. Learn the limits and the symptoms that need care.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

Maya Lee

Glowise Senior GLP-1 Content Editor

Published November 19, 20264 min read
Download the Glowise App

Share this guide

Xfin
An adult preparing a medication list beside a phone for a healthcare conversation

Call 911 in the U.S. for possible lung clot symptoms such as new difficulty breathing, chest pain, coughing up blood, or fainting. New swelling, tenderness, warmth, or red or discolored skin in one leg or arm needs medical assessment as soon as possible. A pulmonary embolism can occur without noticeable signs in the leg or arm. CDC blood clot guidance.

Published case reports describe blood clots in people who took tirzepatide. Comparative studies have also followed people taking the drug. Taken together, the evidence has not established that tirzepatide causes blood clots, and it cannot determine what is causing a new symptom in an individual. That is why the urgency depends on your symptoms even if the medication's role is uncertain.

What kind of blood clot are we talking about?

Deep vein thrombosis (DVT) is a clot in a deep vein, usually in the leg and sometimes in the arm. A pulmonary embolism (PE) can happen if part of a clot breaks loose and travels to the lungs. Together, DVT and PE are called venous thromboembolism (VTE).

VTE is a different outcome from the arterial events counted in many heart attack and stroke studies. A cardiovascular benefit for those events does not establish whether the medicine changes the risk of a clot in a deep vein.

What can a reported clot after tirzepatide tell you?

A 2025 case report describes a person who developed a DVT within months of starting tirzepatide. The authors called it “unprovoked,” meaning their evaluation did not identify a conventional trigger. The patient improved after treatment for the clot and stopping tirzepatide. Those two changes happened together, so the report cannot show how much stopping the drug contributed to the improvement.

A case report documents what happened and when. It cannot show how often the same event would occur in similar people who never took the drug. Even several cases leave that question open. The current U.S. Mounjaro and Zepbound labels do not list DVT or PE as common adverse reactions. A list of common reactions has limited value for judging a rare event.

What changes when a study compares groups?

A 2026 medical-record study compared people with obesity starting tirzepatide with similar people starting other GLP-1 receptor agonists. Tirzepatide starters had a modestly lower recorded rate of DVT or PE over one year (hazard ratio 0.90, 95% confidence interval 0.83–0.98). The study used records to match people on measured factors and had another treated group as the comparison. It could miss relevant differences between the groups and did not establish how tirzepatide affects risk compared with taking neither medicine.

A pooled analysis of randomized GLP-1 trials had meanwhile raised a signal for DVT, with less conclusive findings for PE and for VTE overall. It combined different GLP-1 medicines and did not provide a tirzepatide-specific estimate. DVT, PE, and a combined VTE outcome can give different results. For a headline about blood clots, check the medicine, the comparator, and the kind of clot before applying it to your decision.

What should you do with a new symptom or a past clot history?

Get new one-sided limb swelling, warmth, tenderness, pain, or discoloration assessed promptly. Muscle injury and other conditions can cause similar signs. A clinician may need tests to tell them apart. If breathing becomes difficult, you have chest pain, cough up blood, or feel faint or pass out, seek emergency care immediately. Share your medication list and any history of clots when you get assessed. Collecting a detailed symptom history can wait. CDC information on symptoms and diagnosis.

If you have no new symptoms and are reviewing treatment, bring up any past DVT or PE, a family history of clots, planned surgery, long periods of immobility, or use of estrogen-containing medicines. Those details can matter even without a clear effect from tirzepatide. A useful question if you previously had a clot and are planning surgery is, “Who will review clot prevention while I'm less mobile, and what should that team know about my medicines?” CDC VTE risk factors.

For broader soreness patterns, see our guide to tirzepatide and body aches. New one-sided swelling or concerning chest or breathing symptoms deserve the assessment above.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

About the author

Maya Lee

Glowise Senior GLP-1 Content Editor

Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.

She helps readers ask better questions and keep the details relevant to a care conversation together.

See more Glowise on Google

Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

Glowise library

Bring your GLP-1 routine into one place.

Download the Glowise app to keep medication, meals, hydration, side effects, and progress together.